Antigen Detection Reagent Development Service

Based on the great harm of infectious diseases to human beings, the development of rapid detection reagents is of great practical significance. CD BioSciences constructs targeted peptidomimetic molecules based on various types of antigens to achieve rapid binding and diagnosis, which will be beneficial to the rapid detection of infectious viruses and the early diagnosis and screening of various diseases.

---

Overview of Antigen Detection of COVID-19

Since the outbreak of COVID-19 in 2019, there has been a climax in the research and development of various new detection reagents. In March 2020, after the research and development of nucleic acid reagents mainly based on PCR in the early stage, researchers found that the novel coronavirus gene encodes multiple structural proteins, such as N-protein, E-protein and S-protein, which include multiple antigenic epitopes. Therefore, the antigen detection method of directly detecting the structural protein of novel coronavirus in the sample is more popular.

Fig. 1 Different COVID-19 diagnosis methods based on the type of sample isolated from the patient infected and other criteria.（Singh, et al., 2021）

Advantages of Antigen Detection

• Antibody reagents can be used for rapid diagnosis, but they can not be detected until 3-6 days after the patient is infected with novel coronavirus.
• Nucleic acid reagents can also achieve early diagnosis, but the detection procedure and cycle are long and need to be carried out under laboratory conditions, with high cost and low accuracy due to high false negatives.
• Antigen reagents combine the advantages of nucleic acid reagent and antibody reagent, avoids the problems of long detection time and high false negative of nucleic acid reagent, and solves the problem of "window period" of antibody reagent.

The operation flow of antigen detection reagent is as follows:

Fig. 2 Analytical workflow of rapid antigen test for the rapid detection of viral antigens through lateral flow immunoassay. (Falzone, et al., 2021)

---

Our Services

CD BioSciences provides thousands of types of antigen detection reagent development services. These antigens can come from human, animals or plants.

Based on our peptidomimetic development service, we develop peptidomimetic molecules with the highest binding force with the target antigen, and package the peptidomimetic molecules on solid-phase carriers (including but not limited to magnetic beads, microspheres, membranes, etc.) or liquid-phase chips according to the specific needs of customers, so as to develop peptidomimetic reagents or kits that can effectively and rapidly detect the corresponding antigens.

We can provide antigen detection reagent development including but not limited to the following:

Features of Our Antigen Detection Reagent

Based on immunology-related expertise, CD BioSciences is committed to developing assays for multiple antigen types using our unique peptidomimetic development technology. We focus on the impact of COVID-19 and are committed to developing detection reagents based on its structural proteins, if you are interested in our services, please contact us for the best solution.

References

1. Singh, B., Datta, B., Ashish, A., & Dutta, G. (2021). A comprehensive review on current COVID-19 detection methods: From lab care to point of care diagnosis. Sensors International, 2, 100119.
2. Falzone, L, Gattuso, G., Tsatsakis, A., Spandidos, D., & Libra, M. (2021). Current and innovative methods for the diagnosis of covid19 infection (review). International journal of molecular medicine, 47(6), 100.

Related Services